SLOWING THE DETERIORATION OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY-DISEASE OBSERVED DURING BRONCHODILATOR THERAPY BY ADDING INHALED CORTICOSTEROIDS - A 4-YEAR PROSPECTIVE-STUDY

Objective: To determine if deterioration in patients with asthma or ch ronic obstructive pulmonary disease (COPD) during bronchodilator thera py could be slowed by additional treatment with an inhaled corticoster oid. Design: A 4-year prospective study. Setting: Twenty-nine general practices in the catchment area of the University of Nijmegen, Nijmege n, the Netherlands. Patients: The study included 56 patients (28 with asthma and 28 with COPD) who showed an annual decrease in the forced e xpiratory volume in 1 second (FEV1) of at least 80 mL in combination w ith at least two exacerbations per year during bronchodilator therapy alone. Forty-eight patients completed the study. Intervention: During the first 2 years of treatment, patients received only bronchodilator therapy (salbutamol, 400 mug, or ipratropium bromide, 40 mug). During years 3 and 4, they received additional treatment with beclomethasone dipropionate, 400 mug two times daily. Results: Prebronchodilator FEV1 increased 458 mL/y (95% CI, 233 to 683 mL/y) during the first 6 month s of beclomethasone treatment; FEV1 then decreased 102 mL/y (CI, 57 to 147 mL/y) during months 7 to 24. The annual decline in FEV1 during be clomethasone treatment was less than the decline of 160 mL/y seen befo re beclomethasone therapy (difference, 58 mL/y; 95% CI, 2 to 87 mL/y). Only in patients with asthma did beclomethasone treatment improve bro nchial hyperresponsiveness (assessed by determining the concentration of histamine that provoked a 20% decrease in FEV1 [PC20]) by 3.0 doubl ing doses per year (95% CI, 0.8 to 5.2 doses per year). Beclomethasone treatment was associated with improvement in peak expiratory flow rat e, alleviation of symptoms, and a decrease in the number of exacerbati ons in both patient groups. Conclusion: Adding beclomethasone, 800 mug daily, slowed the unfavorable course of asthma or COPD seen with bron chodilator therapy alone. This effect was most evident in asthmatic pa tients.